Navacims for IBD (Parvus Therapeutics/Genentech)

N/A

Report date: 2025/03/20 16:04:15

Base Information

Drug NameNavacims for IBD (Parvus Therapeutics/Genentech)
Drug Alias NameNavacims for IBD (Parvus Therapeutics)nanoparticles for inflammatory bowel disease (Parvus Therapeutics)
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionImmunomodulatorsT lymphocytes modulators
TargetsUpdating
Therapy Area/IndicationsInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesParvus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesParvus Therapeutics IncGenentech Inc
Inactive CompaniesN/A
Active IndicationsInflammatory Bowel Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A